首页> 美国卫生研究院文献>Journal of Lipid Research >The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats
【2h】

The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats

机译:载脂蛋白A-I模拟肽4F可预防内毒素血症大鼠的血管功能缺陷

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

High density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) reduce inflammatory responses to lipopolysaccharide (LPS). We tested the hypothesis that the apoA-I mimetic peptide 4F prevents LPS-induced defects in blood pressure and vascular reactivity. Systolic blood pressure (SBP) was measured in rats at baseline and 6 h after injection of LPS (10 mg/kg) or saline vehicle. Subgroups of LPS-treated rats also received 4F (10 mg/kg) or scrambled 4F (Sc-4F). LPS administration reduced SBP by 35% compared with baseline. 4F attenuated the reduction in SBP in LPS-treated rats (17% reduction), while Sc-4F was without effect. Ex vivo studies showed a reduced contractile response to phenylephrine (PE) in aortae of LPS-treated rats (ED50 = 459 ± 83 nM) compared with controls (ED50 = 57 ± 6 nM). This was associated with nitric oxide synthase 2 (NOS2) upregulation. 4F administration improved vascular contractility (ED50 = 60 ± 9 nM), reduced aortic NOS2 protein, normalized plasma levels of NO metabolites, and reduced mortality in LPS-treated rats. These changes were associated with a reduction in plasma endotoxin activity. In vivo administration of 14C-4F and Bodipy-LPS resulted in their colocalization and retention in the HDL fraction. It is proposed that 4F promotes the localization of LPS to the HDL fraction, resulting in endotoxin neutralization. 4F may thus prevent LPS-induced hemodynamic changes associated with NOS2 induction.
机译:高密度脂蛋白(HDL)和载脂蛋白A-I(apoA-I)减少了对脂多糖(LPS)的炎症反应。我们测试了apoA-I模拟肽4F防止LPS诱导的血压和血管反应性缺陷的假说。在基线时和注射LPS(10 mg / kg)或生理盐水媒介后6小时,测量大鼠的收缩压(SBP)。 LPS治疗的大鼠的亚组也接受4F(10 mg / kg)或加扰的4F(Sc-4F)。与基线相比,LPS给药可使SBP降低35%。 4F减弱了LPS处理的大鼠的SBP降低(降低17%),而Sc-4F没有效果。体外研究显示,与对照组(ED50 = 57±6 nM)相比,LPS处理的大鼠的主动脉对去氧肾上腺素(PE)的收缩反应降低(ED50 = 459±83 nM)。这与一氧化氮合酶2(NOS2)上调有关。 4F给药改善了血管收缩性(ED50 = 60±9 nM),降低了主动脉NOS2蛋白,NO代谢物的血浆水平正常化,并降低了LPS治疗大鼠的死亡率。这些变化与血浆内毒素活性的降低有关。体内施用 14 C-4F和Bodipy-LPS导致它们共定位并保留在HDL组分中。提出4F促进LPS向HDL部分的定位,导致内毒素中和。因此,图4F可以防止LPS诱导的与NOS2诱导相关的血液动力学变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号